UNION Therapeutics Strengthens Leadership Team With New Executive Appointments

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Irrimax Receives FDA Clearance for Irrisept

"This new clearance from the FDA further solidifies Irrisept as the market leader in wound irrigation," said Mark Alvarez, CEO of Irrimax.

October 28, 2020

UNION Therapeutics A/S (“UNION”), a privately-held clinical-stage pharmaceutical company focusing on infectious and inflammatory diseases, announced further strengthening of the leadership team.

UNION Therapeutics notes that during 2020, UNION has significantly expanded the Company’s pipeline through the advancement of two anti-viral candidates for COVID-19 (inhalation and nasal) into late-stage clinical development, and by completing the acquisition of orismilast, second-generation oral and topical PDE4 inhibitors, from LEO Pharma. Orismilast oral has demonstrated clinical proof-of-concept in psoriasis, while a topical formulation has demonstrated proof-of-concept in patients with atopic dermatitis. These expansions come in addition to ATx201, currently in Phase 2b for atopic dermatitis, bringing the number of later-stage clinical candidates to five.

Dr. Rasmus Toft-Kehler, current Chief Executive Offer (CEO) and Co-Founder of UNION Therapeutics stated: “The expansion of our pipeline has motivated the search for a CEO with a deep and strong track record in late-stage development as well as commercial experience, alongside a proven ability to execute on corporate strategies with a global team. In Dr. Kjoeller, we have found the person to lead UNION through the next chapter of growth and expansion. I am therefore proud and pleased to announce that Dr. Kjoeller, as of January 1, 2021 will be replacing me as CEO to progress UNION’s development with potential approvals and commercial opportunities in sight.”

Dr. Kjoeller added: “Having followed UNION in recent years I have become increasingly impressed with their pipeline, passion, and ability to identify and develop new improved solutions for patients in areas of significant unmet medical need. Joining UNION at this time with the opportunities that have been established through the COVID-19 program and orismilast, I cannot wait to work with the team in order to bring these candidates to patients. I am convinced that the foundation, in terms of both the pipeline and the team, has been solidly established and I look forward to leading UNION through the next chapter of development and into a sustainable success.”

Furthermore, with the addition and advancement of orismilast and the COVID-19 product candidates, UNION will increasingly focus on pharmaceutical innovation and building supply capacity and has appointed Dr. Günter Ditzinger as Chief Technology Officer. Dr. Ditzinger brings 30 years of experience from Sanofi, Novartis and most recently as the Chief Technology Officer of Swiss-based Basilea Pharmaceutica.

“Altogether, these additions to our team are important to ensure continued expansion and the ability to deliver on the ambitious goals set forth by the Board and owners of UNION, Therapeutics with the overarching vision of advancing medicine by listening and responding to patient needs.” concluded Dr. Toft-Kehler.



Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles

Join our list

Subscribe to our mailing list and receive an end-of-week recap news and updates delivered right to your email inbox.